Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CHINOOK THERAPEUTICS, INC. (KDNY) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Amended and Restated Certificate of Incorporation",
"Amended and Restated Bylaws"
08/03/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart for Patients with IgA Nephropathy"
06/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Chinook Therapeutics to Present Updated Data from Zigakibart Phase 1/2 Trial in Patients with IgA Nephropathy at the 60 th European Renal Association Congress"
06/12/2023 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among Chinook Therapeutics, Inc., Novartis AG and Cherry Merger Sub Inc",
"Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG"
05/09/2023 8-K Quarterly results
Docs: "CHINOOK THERAPEUTICS, INC. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Collaboration and license revenue $ 1,828 $ 2,697 Operating expenses: Research and development 50,883 26,252 General and administrative 11,404 7,868 Change in fair value of contingent consideration and contingent value rights liabilities 526 Amortization of intangible assets 433 429 Total operating expenses 63,246 33,511 Loss from operations Investment and other income , net 3,102 Loss before income taxes and equity method investment loss Equity method investment loss Net loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 70..."
04/13/2023 8-K Quarterly results
02/27/2023 8-K Quarterly results
Docs: "Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates SEATTLE February 27, 2023"
02/24/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amended and Restated Bylaws of Chinook Therapeutics, Inc. (as amended and restated on February 23, 2023)",
"Amended and Restated Bylaws of Chinook Therapeutics, Inc. (as amended and restated on February 23, 2023)"
11/10/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors"
03/17/2022 8-K Quarterly results
Docs: "Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results"
01/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/30/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "50/50 joint venture with investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China • Expands global reach and execution for Chinook’s atrasentan and BION-1301 programs in IgA nephropathy SEATTLE November 30, 2021 – Chinook Therapeutics, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the formation of SanReno Therapeutics, a joint venture with an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China, to develop, manufacture and commercialize kidney disease therapies in the People’s Republic of China, Hong Kong, Macau, Taiwan and Singapore . “Formation of this joint venture allows Chinook to expand our global reach ..."
11/10/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement by and among Chinook Therapeutics, Inc. and SVB Leerink and Evercore ISI, as Representatives of the several underwriters",
"Form of Pre-Funded Warrant",
"Opinion of Fenwick & West LLP",
"Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering"
11/08/2021 8-K Quarterly results
Docs: "Chinook Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results"
08/12/2021 8-K Quarterly results
06/17/2021 8-K Quarterly results
06/09/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
04/07/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results"
11/20/2020 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/10/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
10/07/2020 8-K Quarterly results
10/01/2020 8-K Quarterly results
09/23/2020 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/21/2020 8-K Quarterly results
08/31/2020 8-K Entry into a Material Definitive Agreement  Interactive Data
08/18/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy